Abstract
Aging-related decline in immune function is associated with diseases like cancer, atherosclerosis, and neurodegenerative conditions. This study aimed to improve the aging gut microbiota and immune system by introducing a prebiotic oligosaccharide, 2-fucosyllactose (2’-FL), abundant in human breast milk with established health benefits in infants and animal models. 2’-FL was consumed at either of two doses versus placebo by 89 healthy older individuals (average age = 67.3 years) in a 6-week randomized controlled trial. Although the primary endpoint (significant change in the cytokine response score) was not met, consumers of the prebiotic experienced increased levels of Bifidobacterium in the gut microbiota, along with elevated serum levels of insulin, high-density lipoprotein (HDL) cholesterol, and fibroblast growth factor 21 (FGF21) hormone. Multi-omics analysis indicated a systemic response to 2’-FL, which could be detected in blood and urine, showcasing the potential of this prebiotic to provide diverse benefits to aging individuals.
Competing Interest Statement
J.M.C. and R.H.B. are employees of Abbott Laboratories, which is a commercial manufacturer of nutritional products containing HMOs including infant formula. J.L.S is a founder, shareholder, and on the scientific advisory board of Novome Biotechnologies and Interface Biosciences. M.M.C., J.L.S., C.D.G. and Abbott Laboratories have filed a provisional patent application related to this work. The other authors declare no competing interests.
Clinical Trial
NCT03690999
Funding Statement
This work was funded by Abbott Nutrition.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Stanford University Human Subjects Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files. Metagenomic and 16S reads are being submitted to the short read archive (SRA) under the BioProject PRJNA996611 and this manuscript will be updated with additional accessions when the submission is complete. Code and analysis files for this project can be found at https://github.com/SonnenburgLab/RAMP_study_analysis.
